MiRP1与HERG形成IKr通道,并与心律失常有关
G W Abbott1, F Sesti, I Splawski
1Department of Pediatrics, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Connecticut 06536, USA.
Cell
|April 29, 1999
概括
一个新的基因,MinK相关1 (MiRP1),与心律障碍有关. 在MiRP1中发生的突变导致电流减少,导致像长QT综合征这样的心律失常,特别是与某些药物结合使用时.
科学领域:
- 分子生物学分子生物学
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
背景情况:
- 心律不整,如长QT综合征,是突然心脏死亡的重要原因.
- 通道,特别是IKr电流,在心脏再极化中起着至关重要的作用.
- 心脏通道的精确分子组成和调节尚未完全理解.
研究的目的:
- 为了克隆和表征一种新的通道基因,MinK相关1 (MiRP1).
- 调查MiRP1在与HERG.共同表达时形成功能性心脏通道中的作用.
- 识别和分析与心律失常相关的MiRP1基因突变.
主要方法:
- 基因克隆和MiRP1蛋白质的表征.
- 在异质系统中,HERG和MiRP1的功能表达.
- 电生理学记录 (例如,补丁) 来研究通道动力学和导电性.
- 分析与长QT综合征和药物诱导的心律失常相关的MiRP1突变.
主要成果:
- 一个编码MinK相关1 (MiRP1) 的新型基因被确定并描述.
- 一个小的整体膜蛋白MiRP1与HERG共同组合,形成功能性的IKr类通道.
- 确定了三种与长QT综合征和心室动相关的MiRP1错误突变,导致具有改变关门特性的通道.
- 发现一种MiRP1变体通过克拉里思罗米辛增加了通道阻塞,为获得性心律失常提供了一种机制.
结论:
- MiRP1是一个关键的子单元,调节HERG通道功能,类似于原生心脏IKr通道.
- 通过减少电流,MiRP1突变可以导致遗传性心律失常.
- 遗传倾向 (MiRP1突变) 和环境压力因素 (例如药物) 的组合可以导致临床表现的心律失常.
更多相关视频
相关概念视频
Ion Channels
The movement of ions like sodium, potassium, and calcium into and out of the cell is essential to maintain the electrochemical gradient in living cells. The ion channels—a class of membrane transport proteins—help maintain this ionic gradient for the smooth functioning of physiological activities such as maintaining cell size and volume, conducting nerve impulses, and gas and nutrient exchange.
Ion channels are specialized integral membrane proteins on the plasma membrane that allow specific...
Ion channels are specialized integral membrane proteins on the plasma membrane that allow specific...
G-Protein Gated Ion Channels
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Sensory organs,...
Mechanism of Cardiac Arrhythmias
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...


